Wechselwirkungen · Spedra
Spedra 50 mg tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-127415 · Präparat HOS-096405
Medicinal products reducing systemic blood pressure As a vasodilator, avanafil may reduce systemic blood pressure. If Spedra is used in combination with another medicinal product which reduces systemic blood pressure, the additive effects may result in symptomatic hypotension (e.g. dizziness, light-headedness, syncope or near-syncope). In phase III clinical trials no events of “hypotension” but occasional episodes of “dizziness” were observed (see section 4.8). One episode of “syncope” was observed in placebo and one episode on 100 mg of avanafil in phase III clinical trials.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): placebo (HOS-088378)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-07T15:55:00Z · SHA-256 9f3a1264ef001d577393feb260b99952ed079148f452f8976f0be132f469d380 · Passage 0fc05757f76bd508056dfa2e9b3092afe9362c887eb6d63bb021fc861138d300 · Zeichen 841–1423 im Abschnitt